Pharmaceutical firms urged to focus on development of new drug entities

Business sources say that as Ranbaxy Labs in India has been recognized as the world's generic marker with last year's sales of over 1 trillion won, domestic pharmaceutical firms need to give priority to new drug entities as part of efforts to nurture their global competitiveness, since these entities is advantageous in terms of a shorter R&D period based on already established safety and effica...